Which company does Capmatinib come from?
Capmatinib is produced by Novartis and launched under the Tabrecta brand. It was launched in 20205, capmatinib received accelerated approval from the U.S. Food and Drug Administration for the treatment of patients with non-small cell lung cancer whose tumor mutations lead to mesenchymal epithelial transition (MET) exon 14 skipping.

Capmatinibcan cause interstitial lung disease (a group of lung diseases that cause scarring of lung tissue), pneumonitis (inflammation of lung tissue), hepatotoxicity (damage to liver cells), photosensitivity, and embryo-fetotoxicity. Based on clear positive signals from early laboratory studies of phototoxicity in cells, people may be more sensitive to sunlight and should be advised to take precautions to cover their skin, use sunscreen, and not tan while taking capmatinib.
atGEOMETRY Efficacy was demonstrated in the mono-1trial (NCT02414139), a multicenter, non-randomized, open-label, multi-short study enrolling
xa0
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)